vs

Side-by-side financial comparison of Amer Sports, Inc. (AS) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.

Amer Sports, Inc. is the larger business by last-quarter revenue ($1.1B vs $950.5M, roughly 1.1× Astrana Health, Inc.). Amer Sports, Inc. runs the higher net margin — 1.8% vs 0.7%, a 1.1% gap on every dollar of revenue. Amer Sports, Inc. produced more free cash flow last quarter ($92.2M vs $-6.0M).

Amer Sports, Inc. is a Finnish multinational sporting equipment division based in Helsinki, Finland. Established in 1950 as an industrial conglomerate with interests as diverse as tobacco trading, ship owning and publishing, Amer has gradually evolved into a multinational firm devoted to the production and marketing of sporting goods. The company employs over 9,700 people. Since 2018, Amer has been a subsidiary of Chinese retail conglomerate Anta Sports.

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

AS vs ASTH — Head-to-Head

Bigger by revenue
AS
AS
1.1× larger
AS
$1.1B
$950.5M
ASTH
Higher net margin
AS
AS
1.1% more per $
AS
1.8%
0.7%
ASTH
More free cash flow
AS
AS
$98.2M more FCF
AS
$92.2M
$-6.0M
ASTH

Income Statement — Q1 FY2024 vs Q4 FY2025

Metric
AS
AS
ASTH
ASTH
Revenue
$1.1B
$950.5M
Net Profit
$19.0M
$6.6M
Gross Margin
52.8%
Operating Margin
12.4%
1.9%
Net Margin
1.8%
0.7%
Revenue YoY
42.9%
Net Profit YoY
184.4%
EPS (diluted)
$0.05
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AS
AS
ASTH
ASTH
Q4 25
$950.5M
Q3 25
$956.0M
Q2 25
$654.8M
Q1 25
$620.4M
Q4 24
$665.2M
Q3 24
$478.7M
Q2 24
$486.3M
Q1 24
$1.1B
$404.4M
Net Profit
AS
AS
ASTH
ASTH
Q4 25
$6.6M
Q3 25
$373.0K
Q2 25
$9.4M
Q1 25
$6.7M
Q4 24
$-7.8M
Q3 24
$16.1M
Q2 24
$19.2M
Q1 24
$19.0M
$14.8M
Gross Margin
AS
AS
ASTH
ASTH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
52.8%
Operating Margin
AS
AS
ASTH
ASTH
Q4 25
1.9%
Q3 25
2.0%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
Q1 24
12.4%
7.5%
Net Margin
AS
AS
ASTH
ASTH
Q4 25
0.7%
Q3 25
0.0%
Q2 25
1.4%
Q1 25
1.1%
Q4 24
-1.2%
Q3 24
3.4%
Q2 24
3.9%
Q1 24
1.8%
3.7%
EPS (diluted)
AS
AS
ASTH
ASTH
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.05
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AS
AS
ASTH
ASTH
Cash + ST InvestmentsLiquidity on hand
$429.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
Total Assets
$2.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AS
AS
ASTH
ASTH
Q4 25
$429.5M
Q3 25
$463.4M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
AS
AS
ASTH
ASTH
Q4 25
$779.3M
Q3 25
$775.5M
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
AS
AS
ASTH
ASTH
Q4 25
$2.2B
Q3 25
$2.2B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AS
AS
ASTH
ASTH
Operating Cash FlowLast quarter
$114.3M
$-2.9M
Free Cash FlowOCF − Capex
$92.2M
$-6.0M
FCF MarginFCF / Revenue
8.8%
-0.6%
Capex IntensityCapex / Revenue
2.1%
0.3%
Cash ConversionOCF / Net Profit
6.02×
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AS
AS
ASTH
ASTH
Q4 25
$-2.9M
Q3 25
$10.0M
Q2 25
$90.9M
Q1 25
$16.6M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$114.3M
$6.0M
Free Cash Flow
AS
AS
ASTH
ASTH
Q4 25
$-6.0M
Q3 25
$7.4M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$92.2M
$5.6M
FCF Margin
AS
AS
ASTH
ASTH
Q4 25
-0.6%
Q3 25
0.8%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
8.8%
1.4%
Capex Intensity
AS
AS
ASTH
ASTH
Q4 25
0.3%
Q3 25
0.3%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
2.1%
0.1%
Cash Conversion
AS
AS
ASTH
ASTH
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
6.02×
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AS
AS

Americas2$409.6M39%
EMEA1$356.9M34%
Greater China3$205.6M20%
Asia Pacific4$78.2M7%

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

Related Comparisons